Argos Therapeutics Company Profile (NASDAQ:ARGS)

About Argos Therapeutics

Argos Therapeutics logoArgos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ARGS
  • CUSIP:
Key Metrics:
  • Previous Close: $4.70
  • 50 Day Moving Average: $4.95
  • 200 Day Moving Average: $4.78
  • 52-Week Range: $3.45 - $13.97
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.07
  • P/E Growth: 0.00
  • Market Cap: $193.86M
  • Outstanding Shares: 41,246,000
  • Beta: 2.1
Profitability:
  • Net Margins: -6,452.34%
  • Return on Assets: -88.70%
Debt:
  • Debt-to-Equity Ratio: 1.81%
  • Current Ratio: 2.98%
  • Quick Ratio: 2.98%
Additional Links:
Companies Related to Argos Therapeutics:

Analyst Ratings

Consensus Ratings for Argos Therapeutics (NASDAQ:ARGS) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.29 (161.40% upside)

Analysts' Ratings History for Argos Therapeutics (NASDAQ:ARGS)
Show:
DateFirmActionRatingPrice TargetDetails
1/17/2017FBR & CoReiterated RatingBuy$13.00View Rating Details
12/9/2016Needham & Company LLCReiterated RatingBuy$10.00View Rating Details
6/20/2016Piper Jaffray CompaniesReiterated RatingOverweight$11.00View Rating Details
4/19/2016Roth CapitalBoost Price TargetBuy$11.00 -> $18.00View Rating Details
3/30/2016Stifel NicolausLower Price TargetBuy$16.00 -> $10.00View Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$17.00 -> $12.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$17.00 -> $12.00View Rating Details
6/9/2015MLV & Co.Set Price TargetBuy$13.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Argos Therapeutics (NASDAQ:ARGS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2017        
11/14/2016Q3 2016($0.35)($0.32)ViewN/AView Earnings Details
8/10/2016Q2($0.43)($0.48)ViewListenView Earnings Details
5/12/2016Q1($0.56)($0.57)ViewListenView Earnings Details
3/29/2016Q4($0.88)($0.84)ViewListenView Earnings Details
11/16/2015Q315($0.92)($0.97)$158.35 millionViewListenView Earnings Details
8/12/2015Q215($0.80)($0.95)ViewListenView Earnings Details
5/14/2015Q115($0.80)($0.89)ViewListenView Earnings Details
3/30/2015Q314($0.73)($0.83)ViewN/AView Earnings Details
11/13/2014($0.65)($0.77)ViewN/AView Earnings Details
8/13/2014Q214($0.60)($0.61)$1.27 million$1.26 millionViewN/AView Earnings Details
5/13/2014Q114($0.46)($1.05)$1.26 million$0.80 millionViewN/AView Earnings Details
3/27/2014($2.63)($36.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Argos Therapeutics (NASDAQ:ARGS)
Current Year EPS Consensus Estimate: $-1.59 EPS
Next Year EPS Consensus Estimate: $-1.53 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.70)($0.54)($0.62)
Q2 20162($0.58)($0.52)($0.55)
Q3 20162($0.33)($0.32)($0.33)
Q4 20162($0.34)($0.30)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Argos Therapeutics (NASDAQ:ARGS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Argos Therapeutics (NASDAQ:ARGS)
Insider Ownership Percentage: 61.64%
Institutional Ownership Percentage: 15.25%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/7/2016International S PharmstandardMajor ShareholderBuy31,704$4.73$149,959.92View SEC Filing  
9/29/2016International S PharmstandardMajor ShareholderBuy43,618$4.56$198,898.08View SEC Filing  
9/20/2016International S PharmstandardMajor ShareholderBuy41,259$4.77$196,805.43View SEC Filing  
9/19/2016International S PharmstandardMajor ShareholderBuy5,580$4.76$26,560.80View SEC Filing  
9/16/2016International S PharmstandardMajor ShareholderBuy52,512$4.77$250,482.24View SEC Filing  
9/1/2016International S PharmstandardMajor ShareholderBuy16,977$4.78$81,150.06View SEC Filing  
8/24/2016International S PharmstandardMajor ShareholderBuy67,371$4.52$304,516.92View SEC Filing  
8/22/2016International S PharmstandardMajor ShareholderBuy75,474$4.24$320,009.76View SEC Filing  
12/16/2015Andrei Vladimirovich PetrovDirectorBuy5,000$1.80$9,000.00View SEC Filing  
12/16/2015Joan WinterbottomInsiderBuy250$1.83$457.50View SEC Filing  
12/15/2015Alexey Alexandrovic VinogradovDirectorBuy2,000$2.15$4,300.00View SEC Filing  
12/2/2015Jeffrey D AbbeyCEOBuy1,000$3.89$3,890.00View SEC Filing  
11/24/2015Holle Philippe Marie Marce VanDirectorBuy10,000$4.28$42,800.00View SEC Filing  
9/3/2015Holle Philippe Marie Marce VanDirectorBuy12,000$6.27$75,240.00View SEC Filing  
9/1/2015Holle Philippe Marie Marce VanDirectorBuy5,000$6.26$31,300.00View SEC Filing  
8/25/2015Jean LamarreDirectorBuy2,500$6.14$15,350.00View SEC Filing  
8/19/2015Jeffrey D AbbeyCEOBuy5,500$4.75$26,125.00View SEC Filing  
2/12/2014Deventer Sander VanDirectorBuy36,416$8.00$291,328.00View SEC Filing  
2/12/2014International S PharmstandardMajor ShareholderBuy1,275,000$8.00$10,200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Argos Therapeutics (NASDAQ:ARGS)
DateHeadline
News IconArgos Therapeutics, Inc. (NASDAQ:ARGS) Price Target & Session Check - Rockville Register (NASDAQ:ARGS)
rockvilleregister.com - February 17 at 6:32 PM
News IconTrading Center: Following Shares of Argos Therapeutics Inc (ARGS) - Benton Bulletin (NASDAQ:ARGS)
bentonbulletin.com - February 17 at 6:32 PM
News IconChart Watch: Following Indicators on Shares of Argos Therapeutics Inc (ARGS) - The Standard (NASDAQ:ARGS)
6milestandard.com - February 16 at 8:31 AM
News IconNoteworthy Tuesday Option Activity: IMAX, HUBS, ARGS (NASDAQ:ARGS)
www.stockoptionschannel.com - February 15 at 2:16 AM
News IconArgos Therapeutics, Inc. (ARGS) expected to move 5% in response to its earnings report - Post Analyst (NASDAQ:ARGS)
postanalyst.com - February 13 at 9:06 PM
globenewswire.com logoArgos Therapeutics to Participate in 2017 Genitourinary Cancers Symposium - GlobeNewswire (press release) (NASDAQ:ARGS)
globenewswire.com - February 13 at 9:06 PM
finance.yahoo.com logoArgos Therapeutics to Participate in 2017 Genitourinary Cancers Symposium (NASDAQ:ARGS)
finance.yahoo.com - February 13 at 4:05 PM
News IconTrading Center: Following Shares of Argos Therapeutics Inc (ARGS) - Providence Standard (NASDAQ:ARGS)
providencestandard.com - February 8 at 3:53 PM
News IconA Favorite Among Institutions: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Midway Monitor (NASDAQ:ARGS)
midwaymonitor.com - February 8 at 3:53 PM
News IconStock Churning Higher Mid-Day Argos Therapeutics, Inc. (NASDAQ:ARGS) - Aiken Advocate (NASDAQ:ARGS)
aikenadvocate.com - February 6 at 3:37 PM
News IconUnusual Volume Sighted in Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) - Aiken Advocate (NASDAQ:ARGS)
aikenadvocate.com - February 6 at 3:37 PM
seekingalpha.com logoArgos Therapeutics: Interview With CEO Jeff Abbey And VP Communications John Menditto - Seeking Alpha (NASDAQ:ARGS)
seekingalpha.com - February 6 at 3:37 PM
globenewswire.com logoArgos Therapeutics to Participate in BIO CEO and Investor Conference - GlobeNewswire (press release) (NASDAQ:ARGS)
globenewswire.com - February 6 at 3:37 PM
nasdaq.com logoIs the Options Market Predicting a Spike in Argos Therapeutics (ARGS) Stock? - Nasdaq (NASDAQ:ARGS)
www.nasdaq.com - February 6 at 3:37 PM
finance.yahoo.com logoArgos Therapeutics to Participate in BIO CEO and Investor Conference (NASDAQ:ARGS)
finance.yahoo.com - February 6 at 3:37 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in Argos Therapeutics (ARGS) Stock? (NASDAQ:ARGS)
finance.yahoo.com - February 6 at 3:37 PM
investornewswire.com logoSentiments And Ratings Alert: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Investor Newswire (NASDAQ:ARGS)
www.investornewswire.com - February 5 at 3:37 PM
News IconNotable Thursday Option Activity: ARGS, CGI, MNKD (NASDAQ:ARGS)
www.stockoptionschannel.com - February 2 at 3:40 PM
News IconArgos Therapeutics Inc (ARGS) Stock Faces Higher Risks Forward After Forming Bearish Double Bottom (NASDAQ:ARGS)
randolphguide.com - February 2 at 3:40 PM
News IconArgos Therapeutics Inc (ARGS) Stock Faces Higher Risks Forward After Forming Bearish Double Bottom (NASDAQ:ARGS)
randolphguide.com - February 2 at 3:40 PM
News IconStock Dragging Lower Heading Into The Open: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Aiken Advocate (NASDAQ:ARGS)
aikenadvocate.com - February 1 at 3:45 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Argos Therapeutics, Inc. (NASDAQ:ARGS)? - Wall Street Beacon (NASDAQ:ARGS)
wsbeacon.com - January 31 at 3:50 PM
News IconStock in Focus: Argos Therapeutics, Inc. (NASDAQ:ARGS) - The Tribune (NASDAQ:ARGS)
lakecitytribune.com - January 31 at 2:44 AM
News IconHigh Volatility Moving the Needle For Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) - Wall Street Beacon (NASDAQ:ARGS)
wsbeacon.com - January 31 at 2:44 AM
News IconStock Watch for Argos Therapeutics, Inc. (NASDAQ:ARGS) - Gilbert Daily (NASDAQ:ARGS)
gilbertdaily.com - January 29 at 8:33 PM
News IconTechnical Roundup on Shares of Argos Therapeutics Inc (ARGS) - Rives Journal (NASDAQ:ARGS)
rivesjournal.com - January 28 at 8:38 PM
News IconInvestor Watch: Checking in on Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) - The Tribune (NASDAQ:ARGS)
lakecitytribune.com - January 27 at 4:28 PM
News IconStock Looking Bearish Out Of The Gate, Gapping Down: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Aiken Advocate (NASDAQ:ARGS)
aikenadvocate.com - January 27 at 4:28 PM
News IconArgos Therapeutics Inc ARGS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ARGS)
www.bioportfolio.com - January 27 at 2:01 AM
4-traders.com logoArgos Therapeutics, Inc. (NASDAQ:ARGS) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:ARGS)
www.4-traders.com - January 27 at 2:01 AM
News IconTracking Williams %R for Argos Therapeutics Inc (ARGS) - Sherwood Daily (NASDAQ:ARGS)
sherwooddaily.com - January 26 at 8:59 PM
marketexclusive.com logoArgos Therapeutics, Inc. (NASDAQ:ARGS) Files An 8-K Entry into a Material Definitive Agreement - Market Exclusive (NASDAQ:ARGS)
marketexclusive.com - January 26 at 3:57 PM
News IconMonitoring Relative Strength Index Values for Argos Therapeutics Inc (ARGS) - Sherwood Daily (NASDAQ:ARGS)
sherwooddaily.com - January 25 at 3:42 PM
4-traders.com logoArgos Therapeutics : adding 70 jobs at N.C. State's Centennial Campus (NASDAQ:ARGS)
www.4-traders.com - January 24 at 8:57 PM
News IconTicker Watch: Technical Views on Shares of Argos Therapeutics Inc (ARGS) - Sherwood Daily (NASDAQ:ARGS)
sherwooddaily.com - January 24 at 3:56 PM
News IconEarnings in Full Force, Analysts Take Aim at Argos Therapeutics, Inc. (NASDAQ:ARGS) - Wall Street Beacon (NASDAQ:ARGS)
wsbeacon.com - January 24 at 3:56 PM
News IconBrokers Add To Their Ratings On Argos Therapeutics Inc (ARGS ... - NewsDen (NASDAQ:ARGS)
newsden.net - January 23 at 8:44 PM
biz.yahoo.com logoARGOS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princip (NASDAQ:ARGS)
biz.yahoo.com - January 23 at 8:44 PM
News IconTechnical Buzz on Argos Therapeutics, Inc. (NASDAQ:ARGS) - The Tribune (NASDAQ:ARGS)
lakecitytribune.com - January 23 at 3:41 PM
News IconStock Update on Earnings & Estimates for Argos Therapeutics, Inc. (NASDAQ:ARGS) - Aiken Advocate (NASDAQ:ARGS)
aikenadvocate.com - January 23 at 3:41 PM
News IconTrading Scope: Following Levels on Shares of Argos Therapeutics Inc (ARGS) - Sherwood Daily (NASDAQ:ARGS)
sherwooddaily.com - January 22 at 3:36 PM
News IconMA Watch on Shares of Argos Therapeutics Inc (ARGS) - Rives Journal (NASDAQ:ARGS)
rivesjournal.com - January 20 at 9:38 PM
bizjournals.com logoArgos CEO talks commercialization and hiring following expansion (NASDAQ:ARGS)
www.bizjournals.com - January 20 at 9:38 PM
News IconMoving Averages in Focus on Shares of Argos Therapeutics Inc (ARGS) - Sherwood Daily (NASDAQ:ARGS)
sherwooddaily.com - January 20 at 2:52 AM
finance.yahoo.com logoArgos Therapeutics Completes Lease Agreement for Commercial Manufacturing Space on the Centennial Campus of North Carolina State University (NASDAQ:ARGS)
finance.yahoo.com - January 19 at 4:43 PM
News IconEarnings Take Center Stage; Analysts Weighing in on Argos Therapeutics, Inc. (NASDAQ:ARGS) - Aiken Advocate (NASDAQ:ARGS)
aikenadvocate.com - January 16 at 3:38 PM
seekingalpha.com logoArgos Therapeutics: Significant Unrecognized Value - Seeking Alpha (NASDAQ:ARGS)
seekingalpha.com - January 14 at 3:36 PM
investornewswire.com logoArgos Therapeutics, Inc. (NASDAQ:ARGS) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:ARGS)
www.investornewswire.com - January 10 at 3:40 PM
News IconTop Stock With Upside & Growth Potential: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Prospect Journal (NASDAQ:ARGS)
prospectjournal.com - January 3 at 8:29 AM
capitalcube.com logoETFs with exposure to Argos Therapeutics, Inc. : December 27, 2016 (NASDAQ:ARGS)
www.capitalcube.com - December 27 at 3:54 PM

Social

What is Argos Therapeutics' stock symbol?

Argos Therapeutics trades on the NASDAQ under the ticker symbol "ARGS."

Where is Argos Therapeutics' stock going? Where will Argos Therapeutics' stock price be in 2017?

7 brokerages have issued 12-month price targets for Argos Therapeutics' shares. Their forecasts range from $10.00 to $18.00. On average, they expect Argos Therapeutics' stock price to reach $12.29 in the next twelve months.

When will Argos Therapeutics announce their earnings?

Argos Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.

What are analysts saying about Argos Therapeutics stock?

Here are some recent quotes from research analysts about Argos Therapeutics stock:

  • According to Zacks Investment Research, "Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. " (2/7/2017)

  • FBR & Co analysts commented, "We had the opportunity to meet with Argos management and discuss the company outlook and pipeline goals for 2017. As a reminder, Argos is currently conducting a Phase III ADAPT trial in renal cell cancer (RCC). We expect data in June and estimate the company will file a BLA in 1Q18, followed by a potential FDA approval and commercial launch in late 2018." (1/17/2017)

Who owns Argos Therapeutics stock?

Argos Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (0.43%), Wall Street Associates (0.20%) and Keybank National Association OH (0.06%). Company insiders that own Argos Therapeutics stock include Alexey Alexandrovic Vinogradov, Andrei Vladimirovich Petrov, Holle Philippe Marie Marce Van, International S Pharmstandard, Jean Lamarre, Jeffrey D Abbey and Joan Winterbottom.

Who sold Argos Therapeutics stock? Who is selling Argos Therapeutics stock?

Argos Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wall Street Associates.

Who bought Argos Therapeutics stock? Who is buying Argos Therapeutics stock?

Argos Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp. Company insiders that have bought Argos Therapeutics stock in the last two years include Alexey Alexandrovic Vinogradov, Andrei Vladimirovich Petrov, Holle Philippe Marie Marce Van, International S Pharmstandard, Jean Lamarre, Jeffrey D Abbey and Joan Winterbottom.

How do I buy Argos Therapeutics stock?

Shares of Argos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Argos Therapeutics stock cost?

One share of Argos Therapeutics stock can currently be purchased for approximately $4.70.

Argos Therapeutics (NASDAQ:ARGS) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Earnings History Chart

Earnings by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Dividend History Chart

Dividend Payments by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Last Updated on 2/20/2017 by MarketBeat.com Staff